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Juffer P, Jaspers RT, Lips P, Bakker AD, Klein-Nulend J.
Expression of muscle anabolic and metabolic factors in mechani-
cally loaded MLO-Y4 osteocytes. Am J Physiol Endocrinol Metab
302: E389 –E395, 2012. First published November 22, 2011;
doi:10.1152/ajpendo.00320.2011.—Lack of physical activity results
in muscle atrophy and bone loss, which can be counteracted by
mechanical loading. Similar molecular signaling pathways are in-
volved in the adaptation of muscle and bone mass to mechanical
loading. Whether anabolic and metabolic factors regulating muscle
mass, i.e., insulin-like growth factor-I isoforms (IGF-I Ea), mechano
growth factor (MGF), myostatin, vascular endothelial growth factor
(VEGF), or hepatocyte growth factor (HGF), are also produced by
osteocytes in bone in response to mechanical loading is largely
unknown. Therefore, we investigated whether mechanical loading by
pulsating fluid flow (PFF) modulates the mRNA and/or protein levels
of muscle anabolic and metabolic factors in MLO-Y4 osteocytes.
Unloaded MLO-Y4 osteocytes expressed mRNA of VEGF, HGF,
IGF-I Ea, and MGF, but not myostatin. PFF increased mRNA levels
of IGF-I Ea (2.1-fold) and MGF (2.0-fold) at a peak shear stress rate
of 44Pa/s, but not at 22Pa/s. PFF at 22 Pa/s increased VEGF mRNA
levels (1.8- to 2.5-fold) and VEGF protein release (2.0- to 2.9-fold).
Inhibition of nitric oxide production decreased (2.0-fold) PFF-induced
VEGF protein release. PFF at 22 Pa/s decreased HGF mRNA levels
(1.5-fold) but increased HGF protein release (2.3-fold). PFF-induced
HGF protein release was nitric oxide dependent. Our data show that
mechanically loaded MLO-Y4 osteocytes differentially express ana-
bolic and metabolic factors involved in the adaptive response of
muscle to mechanical loading (i.e., IGF-I Ea, MGF, VEGF, and
HGF). Similarly to muscle fibers, mechanical loading enhanced ex-
pression levels of these growth factors in MLO-Y4 osteocytes. Al-
though in MLO-Y4 osteocytes expression levels of IGF-I Ea and
MGF of myostatin were very low or absent, it is known that the
activity of osteoblasts and osteoclasts is strongly affected by them.
The abundant expression levels of these factors in muscle cells, in
combination with low expression in MLO-Y4 osteocytes, provide a
possibility that growth factors expressed in muscle could affect
signaling in bone cells.
osteocytes; mechanical loading; bone remodeling; signaling pathways
PHYSICAL INACTIVITY, AS OCCURS DURING AGING, chronic disease,
or skeletal injury, is associated with osteoporosis and sarcope-
nia (45, 48). Loss of bone mass and muscle mass can be
reversed by increasing the rate at which bone cells and muscle
cells synthesize proteins and/or attenuate the rate of protein
degradation (58). Mechanical loading of muscle and bone
results in cellular adaptation via mechanotransduction. This
alters the rate of protein turnover by activation of signaling
pathways regulating the rate of protein synthesis and/or the rate
of protein degradation (58). Alternatively, mechanical loading
may cause changes in the expression of anabolic and metabolic
growth factors that affect muscle and/or bone cells via auto-
crine, paracrine, and/or endocrine systems (2, 25).
Skeletal muscle mass and oxidative capacity are determined
by the net difference in the rates of synthesis and degradation
of contractile and mitochondrial proteins within a muscle fiber.
Muscle size and oxidative capacity are inversely related (58).
This implicates that muscle size is regulated such that supply
and demand of nutrients and oxygen are matching to meet
functional demand and prevent hypoxia. Since muscle fibers
are multinucleated, the rate of protein synthesis may vary with
the number of myonuclei (46). Changes in muscle contractile
activity stimulate expression of factors that modulate muscle
mass by activating satellite cell proliferation by affecting the
rate of mRNA transcription, mRNA translation, or protein
degradation (6). Hence, a loss or gain of skeletal muscle mass
and/or oxidative capacity follows.
Numerous growth factors are capable of modulating the
adaptation of muscle fiber size and oxidative capacity. The
prime anabolic and metabolic growth factors involved in mus-
cle hypertrophy include insulin-like growth factor-I (IGF-I)
isoforms IGF-I Ea and mechano growth factor (MGF) (22),
hepatocyte growth factor (HGF) (51), vascular endothelial
growth factor (VEGF) (16), and myostatin (41). Expression of
these growth factors is determined largely by mechanical
loading of muscle fibers (22).
In contrast to muscle, in which the systems for synthesis and
degradation of the contractile apparatus all reside within the
muscle cell, bone remodeling requires three different cell
types, i.e., osteoblasts, osteoclasts, and osteocytes (57). During
bone remodeling, bone is constantly renewed by the activity of
osteoclasts, which remove excess bone in places that are
relatively unloaded, and osteoblasts, which form bone in places
that are exposed to loading (37, 57). The initiation of mechan-
ically induced bone formation and bone resorption is orches-
trated by the osteocytes and the mechanosensing cells of bone
(11, 57), although cells from other tissues associated with the
musculoskeletal system can affect bone formation, e.g., bone
morphogenic protein 4 production by tenocytes in tendons (7).
Similarly to muscle fibers, which produce growth factors to
adapt muscle mass to mechanical loading, osteocytes produce
growth factors to orchestrate the adaptation of bone mass and
structure to mechanical loading (55, 57, 59). Since muscle
fibers and osteocytes share the same mesenchymal precursor
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cell, and since mechanical loading affects both muscle and
bone by increasing tissue mass and strength, it is plausible that
both muscle fibers and osteocytes share similar biological
pathways in the regulation of muscle fiber size and bone mass
and structure in response to mechanical loading (25, 33).
Although IGF-I Ea, MGF, VEGF, HGF, and myostatin have
been reported to affect the effector cells involved in bone
remodeling (2, 9, 14, 20, 24, 26, 49, 56, 60), it is largely
unknown whether osteocytes produce these factors in response
to mechanical loading. Therefore, we aimed to determine
whether MLO-Y4 osteocytes express basal levels of the most
widely studied muscle anabolic and metabolic factors and to
assess whether mechanical loading by pulsating fluid flow
(PFF) affects the mRNA levels and/or protein levels of these
growth factors in MLO-Y4 osteocytes.
MATERIALS AND METHODS
Osteocyte culture. MLO-Y4 osteocytes were cultured in -minimal
essential medium (-MEM; Gibco, Paisly, UK) supplemented with 10
g/ml penicillin (Sigma-Aldrich, St. Louis, MO), 10 g/ml strepto-
mycin (Sigma-Aldrich), 50 g/ml fungizone (Gibco), 5% fetal bovine
serum (FBS; Gibco), and 5% calf serum (CS; Gibco) at 37°C in a
humidified atmosphere of 5% CO2 in air. The medium was exchanged
every 3–4 days. The MLO-Y4 osteocytes were kindly provided by Dr.
L. F. Bonewald (University of Missouri-Kansas City, Kansas City,
MO) (34). Upon confluence, cells were harvested using 0.25% trypsin
and 0.1% EDTA in phosphate-buffered saline seeded at 2  105
cells/75 cm2 culture flask (Greiner Bio-One, Kremsmuenster, Austria)
and cultured until the cell layer reached confluence again. MLO-Y4
osteocytes were used for PFF experiments, as described below.
PFF. One day before PFF treatment, MLO-Y4 osteocytes were
harvested from the culture flasks and seeded onto polylysine-coated
(50 g/ml poly-L-lysine hydrobromide; Sigma) glass slides (size
2.5  6.5 cm) at 3  105 cells/glass slide and cultured overnight in
petridishes with 13 ml of culture medium containing 5% FBS and 5%
CS. Then, the culture medium was replaced by -MEM medium
containing 1% FBS and 1% CS. MLO-Y4 osteocytes were incubated
at 37°C in a humidified atmosphere of 5% CO2 in air as well as for 1
h PFF treatment or static control culture.
PFF was applied as described earlier (36). Briefly, PFF was
generated by pumping 13 ml of culture medium through a parallel-
plate flow chamber containing the MLO-Y4 osteocytes. The cells
were subjected to a 5-Hz pulse frequency with a mean shear stress of
0.7 Pa, a pulse amplitude of 0.3 Pa, and a peak shear stress rate of 22
Pa/s (5). Higher shear stresses were generated using a 5-Hz pulse
frequency with a mean shear stress of 1.4 Pa, a pulse amplitude of 1.4
Pa, and a peak shear stress rate of 44 Pa/s. These loading regimes were
carefully designed to mimic the fluid shear stress magnitude (ranging
from 0.8 to 3.0 Pa) that osteocytes experience in vivo (62). Static
control cultures were kept in a petri dish under conditions similar to
the experimental cultures, i.e., at 37°C in a humidified atmosphere of
5% CO2 in air. After 1 h of PFF treatment or static control culture,
MLO-Y4 cells were postincubated for 1, 3, 6, and 24 h.
Inhibition of nitric oxide synthesis. Nitric oxide (NO) production
was inhibited by adding 10 M 1400W to the culture medium 1 h
prior to PFF treatment, during PFF treatment, and during unloaded
postincubation.
Inhibition of protein synthesis. One of the major signaling mole-
cules in protein synthesis is mammalian target of rapamycin (mTOR).
mTOR-mediated protein synthesis was inhibited by adding rapamycin
(0, 5, and 50 M) to the culture medium during PFF treatment and
postincubations.
NO production. NO production was measured as nitrite (NO2)
accumulation in the conditioned medium using Griess reagent con-
taining 1% sulfanylamide, 0.1% naphtylethelene-diamine-dihydro-
chloride, and 2.5 M H3PO4. Serial dilutions of NaNO2 in noncondi-
tioned medium were used as a standard curve. Absorbance was
measured at 540 nm with a microplate reader (Bio-Rad Laboratories).
RNA isolation and real-time PCR. Total RNA was isolated using the
RiboPure Kit (Applied Biosystems, Foster City, CA). Total RNA con-
centration was measured using a Nanodrop spectrophotometer (Nano-
Drop Technologies; Thermo-Fischer Scientific, Wilmington, DE).
mRNA was reverse-transcribed to complementary DNA (cDNA) using a
High Capacity RNA-to-cDNA Kit (Applied Biosystems). Real-time PCR
for determination of mouse IGF-I Ea, MGF, VEGF, HGF, and myostatin
mRNA was performed on the StepOne Real-Time PCR system (Applied
Biosystems). Primers were designed using the Universal Probe Library
from Roche Diagnostics. Primers were as follows: IGF-I Ea, 5=-
GTGTTGCTTCCGGAGCTGTG and 5=-CAAATGTACTTCCTTCT-
GAGTC; MGF, 5=-GGAGAAGGAAAGGAAGTACATTTG and 5=-
CCTGCTCCGTGGGAGGCT; VEGF, 5=-CTGTAACGATGAAGC-
CCTGGAGTG and 5=-GGTGAGGTTTGATCCGCATGATCT; HGF,
5=-GATTATTGCCCTATTTCCCGTTGTG and 5=-TGGCACAG-
GATATTACAGGATGG; myostatin, 5=-TGCTGTAACCTTCCCAG-
GACCA and 5=-GTGAGGGGGTAGCGGCAGCAC; and 18S, 5=-
GTAACCCGTTGAACCCCATT and 5=-CCATCCAATCGGTAG-
TAGCG. Data were analyzed using StepOne version 2.0 software
(Applied Biosystems) and normalized for 18S ribosomal RNA levels.
Protein release. VEGF, HGF, and IGF-I protein levels in condi-
tioned medium were measured by an enzyme-linked immunosorbent
assay (RayBio Mouse ELISA kit; RayBiotech). The detection limits
were as follows: VEGF, 2 pg/ml; HGF, 100 pg/ml; and IGF-I, 4
pg/ml. Absorbance was measured at 450 nm with a microplate reader
(Bio-Rad Laboratories).
Statistical analysis. Data of five separate independent experiments
were obtained. Statistical analyses were performed using SPSS 16.0
(SPSS, Chicago, IL). Groups were compared using ANOVAs with
Bonferroni-adjusted t-tests as post hoc tests. Differences were con-
sidered significant if P 0.05. All data are expressed as means SE.
RESULTS AND DISCUSSION
Expression of muscle anabolic and metabolic factors by
MLO-Y4 osteocytes. Force transmission from muscle via its
tendons to bone is presumed to be one of the primary mecha-
nisms by which muscle mass affects bone remodeling (50).
However, muscle may also modulate the rate of bone turnover
via expression and secretion of growth factors that stimulate
osteogenesis via paracrine or endocrine signaling (2, 25) Here,
we show that anabolic and metabolic regulatory growth factors
in muscle fiber size, i.e., IGF-I Ea, MGF, VEGF, and HGF, are
also basally expressed in MLO-Y4 osteocytes (Fig. 1, A and B).
Expression levels of VEGF and HGF mRNA relative to 18S in
MLO-Y4 osteocytes are in the same order of magnitude as
those reported for muscle cells (28, 39). In contrast, expression
levels of IGF-I Ea and MGF mRNA are substantially lower
(i.e., 10,000-fold) compared with those in muscle cells (31). In
addition, basal mRNA levels of the negative regulator of
muscle growth myostatin were not detectable in MLO-Y4
osteocytes (Fig. 1A), although myostatin is abundantly ex-
pressed in muscle cells (27). This suggests that the reported
inhibitory effects of myostatin on proliferation and differenti-
ation of osteoprogenitor cells (18) likely originate from myo-
statin expression in muscle. This supports the notion that
myostatin is a muscle-specific transforming growth factor-
and hence, supports the presumed existence of paracrine
and/or endocrine communication between muscle and bone
(2, 25, 33).
E390 MUSCLE ANABOLIC AND METABOLIC FACTORS IN OSTEOCYTES
AJP-Endocrinol Metab • doi:10.1152/ajpendo.00320.2011 • www.ajpendo.org
 o
n
 February 6, 2012
ajpendo.physiology.org
D
ow
nloaded from
 
Mechanosensitivity and bone remodeling: role of muscle
anabolic and metabolic factors. Osteocytes play a central role
in bone remodeling by sensing the external mechanical stimuli
and transducing these into signaling molecules like NO and
prostaglandins (35, 36), which modulate the activity of osteo-
blasts and/or osteoclasts. It has already been reported that
anabolic and metabolic growth factors, which play a role in the
regulation of muscle fiber size, i.e., IGF-I Ea, MGF, myostatin,
VEGF, and HGF, also affect the activity of osteoblasts and/or
osteoclasts (2, 9, 14, 15, 20, 24, 26, 49, 56, 60). Since
osteocytes coordinate the activity of osteoblasts and osteoclasts
in the process of mechanical adaptation of bone (57), and
muscle anabolic and metabolic factors are also expressed in
osteocytes, these factors could also play a role in mechanically
induced bone remodeling.
In this study, MLO-Y4 osteocytes were subjected to PFF.
Application of PFF for 1 h to MLO-Y4 osteocytes did not
result in visible changes in cell shape or alignment of the cells
in a particular orientation (data not shown). No cells were
removed by the fluid flow treatment, as assessed by visually
inspecting the cultures before and after PFF treatment.
IGF-I Ea and MGF mRNA levels. In the current study,
mechanical loading of MLO-Y4 osteocytes by PFF with a
shear stress rate of 22 Pa/s did not increase mRNA levels of
IGF-I Ea or MGF (Fig. 2, A and C). Moreover, IGF-I protein
production could not be quantified before or after PFF treat-
ment (data not shown). Loading of rat tibia in situ increases
IGF-I mRNA levels in young osteocytes situated near the
periosteal surface, where IGF-I mRNA is also highly expressed
by the osteoblasts (47). Additionally, IGF-I levels are upregu-
lated in mechanically loaded tibia of ovariectomized mice (67),
when RNA is isolated from whole tibiae. The discrepancy
between the effects of mechanical loading on IGF-I gene levels
in tibia in vivo and our results could be explained by the cell
model we used, the type and/or magnitude of load, and/or the
differences between in vitro and in vivo loading. Osteoblasts
have been shown to express MGF in response to stretch (56).
However, to our knowledge, MGF mRNA levels in mechani-
cally loaded osteocytes have not been studied before. Since
strain and fluid shear stress may activate different mechano-
sensitive signaling pathways in the cell (42), it is conceivable
that not fluid shear stress but strain affects IGF-I Ea and/or
MGF mRNA levels by osteocytes. Alternatively, like in muscle
(30), local strain amplifications in the cytoskeleton may also
occur in bone (66). Therefore, osteocytes in a 3D matrix in
Fig. 1. Expression of muscle anabolic and metabolic factors by MLO-Y4
osteocytes. A: MLO-Y4 osteocytes express IGF-I isoform (IGF-I Ea), mechano
growth factor (MGF), VEGF, and hepatocyte growth factor (HGF) mRNA.
Myostatin mRNA levels were not detectable (ND). B: total protein release
during 24-h culture. MLO-Y4 osteocytes secrete VEGF and HGF protein.
IGF-I protein was ND. Values are means  SE of untreated MLO-Y4
osteocytes. mRNA levels were normalized for 18S ribosomal RNA levels.
Fig. 2. Effect of pulsating fluid flow (PFF) on IGF-I Ea and
MGF mRNA levels in MLO-Y4 osteocytes. Cells were sub-
jected to PFF for 1 h (1-h PFF) and postincubated (without
PFF) for 1, 3, 6, and 24 h. PFF at a peak shear stress rate of 22
Pa/s does not significantly change IGF-I Ea mRNA (A) or MGF
mRNA levels (C) in MLO-Y4 osteocytes. Increasing the peak
shear stress rate to 44 Pa/s increased both IGF-I Ea (B) and
MGF (D) mRNA levels. Values are means  SE of PFF-
treated/over-control ratios (PFF, n  5; PFF high, n  4).
Dashed line, no effect of PFF. Significant effect of PFF; *P 
0.05.
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vivo may be subjected to higher-intensity mechanical stimuli
than osteocytes in a 2D environment. To test whether a higher
magnitude of shear stress affects mRNA levels of IGF-I Ea
and/or MGF in osteocytes, we subjected MLO-Y4 osteocytes
to PFF with a twofold higher peak shear stress rate (i.e., 44
Pa/s). Indeed, higher loads did increase mRNA levels of both
IGF-I Ea (2.1-fold) and MGF (2.0-fold) in MLO-Y4 osteocytes
(Fig. 2, B and D). This suggests that, in vivo, increased mRNA
levels of IGF-I Ea and MGF in osteocytes are to be expected
when higher shear stresses are experienced by the osteocytes.
In muscle, IGF-I Ea is a potent growth factor that stimulates
both the rate of mRNA transcription of contractile proteins (53)
and their rate of translation via phosphatidylinositol-3 kinase/
Akt/mTOR pathway (32). The splice variant of IGF-I, MGF,
seems to be involved in satellite cell activation and migration
of myoblasts and satellite cells, resulting in an increased
myonuclear density in the muscle fiber (44, 65). In muscle,
mRNA levels of both isoforms, IGF-I Ea and MGF, are
upregulated by mechanical loading (27). The anabolic effects
of IGF-I Ea and MGF on bone are less well characterized (19).
In bone, MGF E-peptide (a 23-amino acid peptide encoded the
MGF E-domain) stimulates osteoblast proliferation, whereas
IGF-I Ea stimulates both osteoblast proliferation and differen-
tiation (15, 40). Additionally, recombinant IGF-I has been
shown to stimulate osteoclast differentiation and resorption
activity (25, 63), indicating that IGF-I Ea may increase not
only bone formation but also bone resorption.
Bone formation and bone resorption: role of HGF. We
found that mechanical loading by PFF decreased HGF mRNA
levels in MLO-Y4 osteocytes (Fig. 3A). This decrease did not
result in a decrease in HGF protein release, since PFF even
increased HGF protein release 2.3-fold (Fig. 3B). These results
suggest that the PFF-increased HGF protein levels in the
medium were due to enhancement of translation of HGF
mRNA or protein release from the glycocalyx. To test whether
the increase of HGF protein levels in the medium was caused
by an increased rate of translation, we inhibited phosphoryla-
tion of mTOR by adding rapamycin to the culture medium.
Rapamycin is a well-known inhibitor of mTOR, thereby inhib-
iting mTOR-mediated protein translation (8). In the presence
of rapamycin, the PFF-induced HGF protein production/re-
lease was not abolished (Fig. 3C), which indicates that PFF did
not increase HGF protein release via mTOR-stimulated trans-
lational control. An alternative explanation for the discrepancy
between changes in HGF mRNA levels and HGF protein levels
in MLO-Y4 osteocytes after PFF-treatment may be that, sim-
ilarly to muscle fibers, HGF stored in the glycocalyx is released
from it by the mechanical loading-induced NO production (4).
Such release seems possible for osteocytes, since both muscle
fibers and osteocytes produce NO in response to mechanical
Fig. 3. PFF decreases HGF mRNA levels but increases HGF protein release in MLO-Y4 osteocytes. Cells were subjected to 1-h PFF and postincubated (without
PFF) for 1, 3, 6, and 24 h. A: HGF mRNA levels. B: total HGF protein release per culture. C: addition of rapamycin, an inhibitor of protein synthesis, did not
affect PFF-induced HGF protein release. D: 1400W inhibits the PFF-induced nitric oxide (NO) synthesis at 15 min after PFF treatment. E: addition of NO
synthase inhibitor 1400W decreased PFF-induced HGF protein release at 24 h postincubation. Values are means  SE of PFF-treated/over-control ratios or total
protein [n  5 (A and B), n  3 (C), and n  4 (D and E)]. Dashed line, no effect of PFF. Significant effect of PFF; *P  0.05. Significant effect of 1400W;
#P  0.05.
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loading (13, 63). Therefore, we tested whether the PFF-in-
duced HGF protein release by MLO-Y4 osteocytes was medi-
ated by NO. For this purpose, PFF-induced NO production was
inhibited by adding the NO synthase inhibitor 1400W (Fig.
3D). Inhibition of NO synthesis decreased the PFF-induced
HGF protein release 2.0-fold (Fig. 3E), suggesting that NO
modulates HGF protein secretion by osteocytes in response to
mechanical loading.
HGF plays a role in bone formation, because it stimulates
osteoblast differentiation (29) and inhibits mineralization (54).
HGF is also involved in bone resorption, because it stimulates
osteoclast formation (1, 23). Osteoclastic bone resorption is
generally followed by osteoblast differentiation and new bone
deposition, i.e., the activity of osteoclasts and osteoblasts is
tightly coupled (3). Since it is likely that osteocytes orchestrate
the activity of osteoclasts and osteoblasts in the process of
mechanical adaptation of bone (10, 55, 57, 59), bone remod-
eling might be mediated by HGF produced by mechanically
loaded osteocytes. The impact of HGF on bone remodeling and
the precise role of HGF in this warrant further investigation.
Angiogenesis in bone: role of VEGF. In our study, we show
that VEGF mRNA levels and VEGF protein release in
MLO-Y4 osteocytes were increased in response to PFF (Fig. 4,
A and B). VEGF expression is also upregulated in mechani-
callliy loaded tibia of ovariectomized mice (67). Since VEGF
mRNA levels in muscle and endothelial cells are increased by
NO (21), we tested whether the PFF-induced VEGF protein
release by MLO-Y4 osteocytes was also mediated by NO.
Inhibition of NO synthesis by 1400W decreased the PFF-
induced VEGF protein release twofold (Fig. 4C), suggesting
that VEGF expression by osteocytes in response to mechanical
loading is partially modulated by NO like in muscle.
Vascularization in muscle is very important for the supply of
nutrients and oxygen to muscle fibers (17). A limited supply
implicates a low fatigue resistance, which becomes apparent
via a reduction in the ability to generate force (17). Similarly,
as in muscle, a high demand of nutrients and oxygen is to be
expected in bone, particularly since in vitro hypoxia activates
osteoblasts to form bone (61). During bone remodeling, resorp-
tion and formation of the bone matrix are generally accompa-
nied by angiogenesis in the cutting cone of the osteon (3). It
has been reported recently that VEGF, a potent regulator of
angiogenesis, is produced by osteocytes (12). Since bone
remodeling is induced mechanically, and since we showed that
mechanical loading stimulates VEGF mRNA levels and pro-
tein release in MLO-Y4 osteocytes, this might implicate that
the mechanically induced VEGF production contributes to the
vascularization within the cutting cone of the osteon.
VEGF not only stimulates blood vessel formation but also
increases bone formation by stimulating osteoblastogenesis
(20). Therefore, the PFF-induced VEGF production in osteo-
cytes is likely not only contributing to the vascularization
within the bone matrix but is also involved in mechanically
induced bone remodeling.
Summary. The present data show that mechanically loaded
MLO-Y4 osteocytes differentially express mRNA and protein
of anabolic and metabolic factors involved in the adaptive
response of muscle to mechanical loading, i.e., IGF-I Ea, MGF,
VEGF, and HGF. Comparison of these results with those in
muscle suggest similarities as well as differences in signaling
pathways in bone and muscle in response to mechanical load-
ing. Mechanical loading affects VEGF and HGF mRNA and
protein levels in osteocytes, which is also known for muscle
fibers. This indicates novel roles for VEGF and HGF in
mechanical loading-mediated bone remodeling. We also show
that mechanical loading by PFF increases IGF-I Ea and MGF
mRNA levels in MLO-Y4 osteocytes at a high physiological
shear stress rate, but these mRNA levels are still several orders
of magnitude lower than IGF-I Ea and MGF mRNA levels in
muscle (31). MLO-Y4 osteocytes, either subjected to PFF or
not, do not express myostatin mRNA. In muscle, IGF-I Ea,
MGF, and myostatin are highly expressed (31, 38), and the
effect of mechanical loading on the expression of these growth
factors is substantial (26). Although in MLO-Y4 osteocytes
expression levels of IGF-I Ea and MGF were shown to be low
and that of myostatin was not detectable, the activity of
osteoblasts and osteoclasts is well known to be strongly af-
fected by these growth factors (14, 15, 23–25, 43, 52, 60, 64).
This, in combination with the abundant expression levels of
these factors in muscle cells, suggests that osteoblasts and
osteoclasts may, in addition to the growth factors expressed in
these cells, also respond to muscle-derived IGF-I and myosta-
Fig. 4. PFF increases VEGF mRNA levels and VEGF protein release in MLO-Y4 osteocytes. Cells were subjected to PFF for 1 h (1-h PFF) and postincubated
(without PFF) for 1, 3, 6, and 24 h. A: VEGF mRNA levels. B: total VEGF protein release per culture. C: addition of NO synthase inhibitor 1400W decreased
PFF-induced VEGF protein release at 6 h postincubation. Values are means  SE of PFF-treated/over-control ratios or total protein (n  5). Dashed line, no
effect of PFF. Significant effect of PFF; *P  0.05 and **P  0.01. Significant effect of 1400W; ##P  0.01.
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tin. Our results do not provide direct evidence for any paracrine
and/or endocrine signaling between muscle and bone, but such
communication may not be excluded. Whether muscle-derived
growth factors affect bone cells and vice versa requires further
investigation. Additional in vivo research on the biological
cross-talk between bone cells and muscle cells may reveal new
targets for prevention and/or treatment of sarcopenia and os-
teoporosis.
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